Coexistence HBsAg/HBcAC, Clinical CharacterĂstics & Outcomes
Study Details
Study Description
Brief Summary
HBV infection is a dynamic process with complex interactions between virus replication and the host's immune response. The appearance of anti-HBs after HBV infection generally indicates recovery and immunity to HBV1 infection. However, there are several published studies that describe the coexistence of the marker of chronic infection (HBsAg +) and the marker of functional cure (HBsAc +). There are contradictory studies on whether the coexistence of HBsAg/HBsAc implies a different clinical course.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Not apply None. Just registration epidemiology dates |
Outcome Measures
Primary Outcome Measures
- prevalence concomitant HBsAg and HBsAc markers [10 years]
To describe the prevalence of concomitant HBsAg and HBsAc markers in our area
Secondary Outcome Measures
- differences between immunocompetent patients with respect to immunocompromised ones. [10 years]
To compare if there are differences in the prevalence or clinical outcome according if the patient has any degree of immunosupresion or not.
Eligibility Criteria
Criteria
Inclusion Criteria:
- all those patients who have been seen in outpatient hepatology consultations and who present positive HBsAg and HBsAc serology simultaneously.
Exclusion Criteria:
- Hepatitis C or HIV Co-infection
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | H. Consorci Sanitari Parc Tauli | Sabadell | Barcelona | Spain |
Sponsors and Collaborators
- Corporacion Parc Tauli
- Hospital Mutua de Terrassa
- Consorci Sanitari de Terrassa
- Hospital Universitario La Fe
- Germans Trias i Pujol Hospital
- Consorci Hospitalari de Vic
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2022/5032